AgeX Therapeutics (AgeX Therapeutics) Operating Cash Flow per Share : $-7.23 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is AgeX Therapeutics Operating Cash Flow per Share?

AgeX Therapeutics's operating cash flow per share for the three months ended in Dec. 2023 was $-1.90. AgeX Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.23.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -225.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -111.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for AgeX Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

AGE' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -225.5 Med: -88.55 Max: 3.2
Current: -225.5

During the past 7 years, AgeX Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 3.20% per year. The lowest was -225.50% per year. And the median was -88.55% per year.

AGE's 3-Year OCF Growth Rate is ranked worse than
98.63% of 1241 companies
in the Biotechnology industry
Industry Median: 3.7 vs AGE: -225.50

AgeX Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for AgeX Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AgeX Therapeutics Operating Cash Flow per Share Chart

AgeX Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-9.59

-7.30

-7.29

-191.58

-251.61

AgeX Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-1.22	-1.73	-1.87	-1.73	-1.90

Competitive Comparison of AgeX Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, AgeX Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AgeX Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgeX Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where AgeX Therapeutics's Price-to-Operating-Cash-Flow falls into.

AgeX Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

AgeX Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-7.8	/	0.031
	=	-251.61

AgeX Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-2.052	/	1.079
	=	-1.90

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.23

AgeX Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AgeX Therapeutics (AgeX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (AMEX:AGE) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

0X4:Germany 0X4:Germany

Address

1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501

Website

https://www.agexinc.com

AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.

Executives

Jean-christophe Renondin	director	505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp.	director, 10 percent owner	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Joanne M. Hackett	director	C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708
Park Andrea Eun Jae	officer: Chief Financial Officer	C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501
Michael H May	director	965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501
Michael D West	director, officer: Chief Executive Officer	AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Michael H. Mulroy	director	1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Russell Skibsted	officer: Chief Financial Officer	15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Judith Segall	officer: Corporate Secretary	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Hal Sternberg	officer: Vice President-Research	935 PARDEE STREET, BERKELEY CA 94710
Annalisa Jenkins	director	C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
John F Mauldin	director	3204 BEVERLY DRIVE, DALLAS TX 75205
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
Juvenescence Ltd	10 percent owner	1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB
Nafees Naseer Malik	officer: Chief Operating Officer	C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501